Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Aquestive Therapeutics, Inc. (AQST) AI Forecast

Our AI analyzed Aquestive Therapeutics, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$AQST Neutral Signal Full forecast available
Sign Up Free

Aquestive Therapeutics, Inc. (AQST) Stock Forecast Sept. 2, 2026

Aquestive Therapeutics, Inc. (AQST) AI Stock Price Forecast & Investment Analysis

Aquestive Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Aquestive Therapeutics, Inc. (AQST) - Comprehensive Stock Analysis & Investment Research

Deep dive into Aquestive Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 2, 2026, 10:02 a.m. (UTC)

Aquestive Therapeutics, Inc. Investment Summary

When evaluating whether Aquestive Therapeutics, Inc. (AQST) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Aquestive Therapeutics, Inc. (AQST) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $658 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Aquestive Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Aquestive Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Aquestive Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Aquestive Therapeutics, Inc.

Sign Up Free
Corporate Identity

Aquestive Therapeutics, Inc. (Stock Symbol: AQST) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Aquestive Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Aquestive Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Aquestive Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Aquestive Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis

Aquestive Therapeutics, Inc. generates annual revenues of $54 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Aquestive Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Aquestive Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Aquestive Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Aquestive Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Aquestive Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Aquestive Therapeutics, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Aquestive Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-23 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Asset Utilization Efficiency

Asset turnover ratio of 0.41x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Current ratio of 7.19 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Aquestive Therapeutics, Inc. (AQST) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Aquestive Therapeutics, Inc. stock analysis.

Deep dive into Aquestive Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Aquestive Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Aquestive Therapeutics, Inc.:

Market Cap $658M
Revenue/Share $0.43
FCF/Share $-0.18
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Aquestive Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Aquestive Therapeutics, Inc.: An ROE of 229.0% demonstrates excellent shareholder value creation.

ROE 229.0%
ROA -98.1%
ROIC -94.7%
Operating Margin -73.3%
Net Margin -86.8%
EBT Margin -86.8%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Aquestive Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Aquestive Therapeutics, Inc.: A current ratio of 7.19 indicates strong liquidity.

Current Ratio 7.19x
Quick Ratio 6.74x
D/E Ratio -3.33x
Financial Leverage -2.33x
Interest Coverage -3.6x
Working Capital $102M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Aquestive Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Aquestive Therapeutics, Inc.: Free cash flow of $-23M indicates cash challenges that need attention.

Operating Cash Flow $5M
Free Cash Flow -$23M
Capital Spending -$28M
FCF/Sales -41.7%
CapEx/Sales 51.3%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Aquestive Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Aquestive Therapeutics, Inc.: An asset turnover of 0.41x suggests room for improvement in asset utilization.

Asset Turnover 0.41x
Receivables Turnover 5.8x
Fixed Assets Turnover 13.7x
Days Sales Outstanding 63 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Aquestive Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Aquestive Therapeutics, Inc.: With annual revenue of $54M, Aquestive Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $54M
Operating Income -$109M
Net Income -$129M
R&D Expense $52M
SG&A Expense $165M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 118%
Cash & Short-term Investments 98%
Total Liabilities 189%
Short-term Debt 8%
Accounts Receivable 9%
Inventory 7%
Dividend & Shareholder Information
Shares Outstanding 126M
Growth Metrics (YoY)
Net Income Growth -86.8%

Latest Aquestive Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Aquestive Therapeutics, Inc. (AQST) stock price and investment outlook.

📰 Loading...

Where AQST sits on the market map

Explore the map →

Aquestive Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Aquestive Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AAGH ██% N/A x x
AARD ██% $130M x 1.7x
ABBV ██% $459.96B 72.9x x
ABCL ██% $3.46B x 3.9x
ABEO ██% $342M x 2.7x
ABT ██% $189.81B 30.2x 3.7x
ABUS ██% $1.01B 6.6x 3.9x
ABVC ██% $21M x 2.1x
ABVX ██% $8.93B x x
ACAD ██% $4.97B 13.1x 3.8x
ACET ██% $81M x 0.7x
ACRS ██% $846M x 6.8x
ACRV ██% $89M x 1.0x
ACUT ██% $3M x x
ACXP ██% $7M x 0.8x
ADAG ██% $244M x 6.5x
ADCT ██% $158M x x
ADIL ██% $17M x x
ADTX ██% $8M x x
ADXN ██% $5M x x
AEON ██% $14M x x
AGIO ██% $2.03B x 2.0x
AKBA ██% $257M x 10.3x
AKTX ██% $20M x 1.1x
ALDX ██% $90M x 2.4x
ALKS ██% $7.91B 119.6x 4.4x
ALLR ██% $23M x 6.4x
ALMS ██% $1.19B x 2.6x
ALNY ██% $32.91B 41.0x 24.3x
ALT ██% $601M x 1.3x
ALXO ██% $267M x 2.0x
ALZN ██% $8M x 10.8x
AMLX ██% $3.77B x 15.7x
AMPH ██% $977M 12.4x 1.3x
AMRN ██% $292M x 0.7x
AMRX ██% $5.64B 35.9x 170.9x
ANAB ██% $1.60B x 125.9x
ANEB ██% $13M x 1.6x
ANIP ██% $1.52B 14.1x 2.6x
ANIX ██% $111M x 7.7x
ANNX ██% $983M x 5.3x
ANRO ██% $1.38B x 6.3x
ANTX ██% $199M x 2.6x
ANVS ██% $72M x x
APLM ██% $78M x x
APRE ██% $10M x 0.3x
APUS ██% $5M x 0.1x
APVO ██% $4M x 0.7x
AQST ██% $658M x x
ARCT ██% $461M x 2.7x
ARDX ██% $937M x 6.3x
ARQT ██% $2.98B 104.6x 13.5x
ARTL ██% $3M x 0.7x
ARVN ██% $606M 65.2x 1.1x
ARWR ██% $11.68B x 25.1x
ASBP ██% $12M x 1.1x
ASMB ██% $698M x 2.3x
ASND ██% $16.13B x x
ASRT ██% $151M x 2.0x
ATAI ██% $2.72B x 17.0x
ATHE ██% $83M x x
ATNM ██% $31M 1.2x 1.0x
ATOS ██% $24M x 0.9x
ATXI ██% $1M x 2.6x
AUPH ██% $2.13B 6.8x 3.5x
AVBP ██% $1.45B x 4.0x
AVIR ██% $440M x 2.2x
AVLN ██% $1.56B x 3.9x
AVTX ██% $1.02B x 2.3x
AXIM ██% $1M x x
AXSM ██% $10.61B x 127.3x
AZTR ██% $11M x 1.5x
BBIO ██% $14.95B x x
BBOT ██% $707M x 2.2x
BCAX ██% $1.54B x 3.3x
BCTX ██% $32M x 1.3x
BCYC ██% $286M x 0.6x
BDPT ██% $10K x x
BDRX ██% $800K x x
BFRG ██% $9M x 1.3x
BFRI ██% $22M x 3.7x
BHC ██% $2.42B x x
BHST ██% $44M x 1.7x
BIOA ██% $436M x 1.2x
BIOE ██% $10M 6.7x 4.4x
BIOM ██% $480K x x
BIVI ██% $19M x 1.8x
BIXT ██% $2M x x
BLRX ██% $14M x x
BLTE ██% $6.16B x 8.0x
BMEA ██% $130M x 10.8x
BMRN ██% $12.55B 172.0x 2.0x
BMY ██% $138.69B 14.9x 6.2x
BNTC ██% $423M x 2.3x
BOLD ██% $65M x 1.0x
BOLT ██% $7M x 0.6x
BPTH ██% $1M x x
BQST ██% $2M x x
BRNS ██% $31M x 0.6x
BSPK ██% $10K x x
BTAI ██% $4M x x
BYSI ██% $25M x x
CALC ██% $15M x 2.7x
CANF ██% $7M x 1.3x
CAPR ██% $582M x 2.4x
CATX ██% $361M x 1.1x
CBIO ██% $666M x 6.2x
CDT ██% $1M x 0.0x
CING ██% $71M x 3.0x
CLCS ██% $65M x x
CLNN ██% $55M x x
CLRB ██% $23M x 0.8x
CLSDQ ██% $1M x x
CLYM ██% $789M x 3.3x
CMMB ██% $20M x 1.6x
CMND ██% $3M x x
CMPS ██% $1.80B x 21.3x
CNBX ██% N/A x x
CNSP ██% $8M x 0.5x
CNTA ██% $6.27B x 12.9x
CNTB ██% $149M x 5.5x
CNTX ██% $33M x 0.9x
COCP ██% $22M x 21.2x
COGT ██% $6.30B x 11.8x
COLL ██% $862M 18.0x 2.8x
CORT ██% $11.95B 216.5x 16.9x
COYA ██% $106M x 2.4x
CPHI ██% $36M x 1.0x
CPIX ██% $98M x 5.6x
CPMD ██% $2M x x
CPRX ██% $3.85B 17.4x 3.8x
CRBP ██% $211M x 2.1x
CRMD ██% $651M 3.5x 1.4x
CRNX ██% $8.99B x 7.5x
CRVO ██% $39M x 1.7x
CRVS ██% $1.20B x 5.3x
CTMX ██% $727M x 2.4x
CTNM ██% $620M x 2.6x
CTOR ██% $79M x 2.0x
CTTH ██% $3M x 3.9x
CTXR ██% $16M x 0.2x
CUE ██% $207M x 89.4x
CURX ██% $7M x 1.5x
CVKD ██% $5M x 1.3x
CVSI ██% $4M x 2.3x
CYCN ██% $18M x 3.5x
CYDY ██% $301M x x
CYPH ██% $184M x 1.3x
CYRX ██% $788M x 1.6x
CYTK ██% $9.93B x x
DARE ██% $15M x x
DCOY ██% $2M x 0.5x
DERM ██% $204M x 6.3x
DMAC ██% $348M x 9.1x
DMRA ██% $1.74B x 3.4x
DNTH ██% $5.84B x 5.0x
DRMA ██% $6M x 1.9x
DRUG ██% $695M x x
DSGN ██% $944M x 4.7x
DWTX ██% $88M x 1.3x
DYN ██% $4.69B x 6.7x
EBS ██% $319M x 0.9x
EDSA ██% $46M x 5.2x
ELAB ██% $4M x 0.2x
ELAN ██% $11.94B x 1.8x
ELDN ██% $243M x 7.4x
ELTP ██% $312M 5.5x 3.0x
ELTX ██% $67M x 8.5x
ELVN ██% $4.24B x 4.7x
EMMA ██% $5M x x
ENLV ██% $22M 0.0x 0.0x
ENSC ██% $8M x x
ENTA ██% $388M x 3.8x
ENVB ██% $6M x 0.8x
EOLS ██% $599M x x
EPRX ██% $419M x 5.1x
EQ ██% $140M x 2.5x
ERAS ██% $5.86B x 16.2x
ERNA ██% $5M x 1.6x
ESPR ██% $799M x x
ETON ██% $1.71B 134.7x 36.7x
ETST ██% $27M 6.2x 3.7x
EVFM ██% $1M x x
EVMN ██% $453M x 1.6x
EWTX ██% $4.55B x 10.2x
FBIO ██% $89M 0.8x 0.5x
FBLG ██% $14M x 3.0x
FBRX ██% $1.58B x 8.6x
FHTX ██% $337M x x
FLNA ██% $41M x 0.6x
FTH ██% $847M x 4.9x
FULC ██% $295M x 1.0x
GALT ██% $421M x x
GANX ██% $77M x 6.8x
GCAN ██% $300K 0.3x x
GDTC ██% $11M x x
GENB ██% $2.03B x 4.4x
GERN ██% $951M x 4.4x
GHRS ██% $1.70B x x
GLMD ██% $4M x 0.3x
GLSI ██% $219M x 70.4x
GNLX ██% $117M x 7.2x
GNPX ██% $3M x 0.2x
GOSS ██% $85M x x
GOVX ██% $3M x 1.8x
GPCR ██% $3.27B x 2.4x
GRCE ██% $45M x 0.9x
GRI ██% $4M x 0.4x
GRTX ██% $3.38B 22.7x 4646.0x
GSK ██% $100.64B x x
GTBP ██% $13M x 3.6x
GYRE ██% $686M x 6.4x
HCM ██% $2.07B 2.3x 1.7x
HCWB ██% $7M x 1.1x
HELP ██% $848M x x
HEPA ██% $7M x 5.3x
HIND ██% $15M x 2.5x
HOOK ██% $14M x 0.4x
HOWL ██% $47M x 2.9x
HRMY ██% $2.40B 13.2x 2.4x
HRTX ██% $61M x 8.8x
HSTC ██% $92M x 74.2x
HURA ██% $129M x 7.0x
HYFT ██% $63M x x
HYPD ██% $47M 7.1x 0.5x
IBIO ██% $81M x 0.9x
IBO ██% $49M 62.5x 4.6x
IDYA ██% $3.86B x 3.2x
IFRX ██% $314M x x
IGC ██% $31M x 5.0x
IMMP ██% $55M x x
IMMX ██% $1.00B x 4.4x
IMNM ██% $3.07B x 5.8x
IMNN ██% $9M x 2.2x
IMRN ██% $9M x x
IMRX ██% $314M x 1.7x
IMUX ██% $199M x 1.6x
INBP ██% $6M x 0.3x
INDP ██% $151M x 13.2x
INDV ██% $4.16B 13.5x x
INM ██% $7M x 1.1x
INO ██% $138M x 31.5x
INSM ██% $26.34B x 34.8x
INTI ██% $12M x x
INVA ██% $1.53B 3.8x 1.2x
IOBTQ ██% $10K x 0.0x
IONS ██% $10.00B x 22.7x
IRD ██% $317M x x
IRON ██% $3.02B x 4.7x
IRWD ██% $706M 5.4x x
ISCO ██% $3M x x
IVA ██% $1.13B x x
IXHL ██% $40M x 0.5x
JAGX ██% $4M x 0.6x
JANX ██% $1.15B x 1.2x
JAZZ ██% $15.40B 16.4x 3.2x
JBIO ██% $1.34B x 3.0x
JNJ ██% $652.86B 31.0x 7.7x
JUNS ██% $4M x x
KALA ██% $10M x 1.1x
KALV ██% $1.38B x x
KAPA ██% $6M x 1.3x
KAYS ██% $70K x x
KLRA ██% $2.13B x 1.9x
KMDA ██% $483M x x
KNSA ██% $6.07B 83.0x 10.0x
KPRX ██% $10M x 0.7x
KPTI ██% $47M x x
KROS ██% $219M x 0.8x
KRRO ██% $184M x 1.8x
KTTA ██% $19M x 0.4x
KURA ██% $1.15B x 23.7x
KYNB ██% $32M 0.2x x
LAB ██% $255M 3.0x 0.5x
LABT ██% $7M x 1.5x
LBRX ██% $1.52B x 4.6x
LEGN ██% $4.04B x x
LEXX ██% $19M x 3.9x
LFCR ██% $165M x x
LFVN ██% $78M 15.4x 2.3x
LGND ██% $5.66B 28.7x 5.9x
LGVN ██% $22M x 2.1x
LIANY ██% $12M x 0.1x
LIFD ██% $1M x 0.2x
LIPO ██% $0.00M x 0.0x
LITS ██% $35M x 0.6x
LIXT ██% $120M x 15.2x
LKFT ██% $1.88B x x
LLY ██% $1.04T 38.8x 30.6x
LNAI ██% $10M x x
LPCN ██% $19M x 0.9x
LQDA ██% $5.96B 43.0x 30.6x
LRMR ██% $409M x 3.2x
LSTA ██% $14M x 1.7x
LTRN ██% $26M x x
LXRX ██% $979M x 5.6x
LYEL ██% $340M x 1.5x
MAIA ██% $79M x 3.8x
MANE ██% $4.29B x 5.3x
MBIO ██% $4M x 0.6x
MBRX ██% $13M x 1.1x
MBX ██% $2.92B x 7.1x
MCRB ██% $51M x 1.5x
MDCX ██% $17M x x
MDGL ██% $12.44B x 23.8x
MEDS ██% $3M x 0.1x
MGNX ██% $257M x 6.0x
MIRA ██% $36M x 4.4x
MIRM ██% $6.37B x x
MIST ██% $142M x 7.8x
MLTX ██% $1.29B x 3.0x
MLYS ██% $2.27B x 4.1x
MNKD ██% $1.23B x x
MNOV ██% $71M x 1.9x
MNPR ██% $772M x 5.9x
MPLT ██% $605M x 1.7x
MREO ██% $44M x 1.5x
MRK ██% $370.15B 116.7x 8.8x
MRKR ██% $22M x 1.8x
MRVI ██% $2.83B x 13.8x
MSLE ██% $193M x x
MTNB ██% $3M x 1.6x
MTVA ██% $11M x 1.7x
NAMS ██% $2.93B x 4.6x
NATR ██% $244M 13.5x 1.4x
NBP ██% $200M x 0.8x
NBTX ██% $1.90B x x
NCEL ██% $19M x 35.0x
NCNA ██% $6M x x
NERV ██% $215M x x
NEUP ██% $20M x 0.7x
NGNE ██% $758M x 3.5x
NIKA ██% $431M x x
NKTR ██% $2.45B x 2.7x
NKTX ██% $196M x 0.8x
NMAD ██% $75M x 3.1x
NNVC ██% $31M x 3.4x
NRIX ██% $2.67B x 6.6x
NRSN ██% $16M x x
NRXP ██% $150M x x
NSRX ██% $45M x 16.2x
NTHI ██% $123M x x
NUVB ██% $2.30B x 9.1x
NUVL ██% $9.75B x 8.3x
NVCT ██% $753M x 82.9x
NVS ██% $307.69B x x
NWBO ██% $284M x x
NXTC ██% $31M x 2.6x
NXTS ██% $3M x 1.3x
OCUL ██% $2.32B x 4.5x
OGEN ██% $2M x 0.6x
OGI ██% $171M x x
OGN ██% $3.61B 17.3x 3.6x
OKUR ██% $144M x 0.8x
OLMA ██% $923M x 2.2x
OMER ██% $1.35B 10.8x x
ONC ██% $40.68B 62.0x 7.9x
ONCO ██% $2M x 0.2x
ONCY ██% $105M x x
OPK ██% $1.11B x 0.9x
ORGO ██% $210M x 1.4x
ORIC ██% $1.34B x 3.5x
ORKA ██% $5.66B x 5.1x
ORMP ██% $207M 1.2x 0.7x
OSTX ██% $77M x x
OTLC ██% $15M x 0.1x
OVID ██% $510M x 2.4x
OWPC ██% $10K x x
PAHC ██% $1.53B 15.4x 4.0x
PBH ██% $2.46B 14.3x 1.3x
PBM ██% $10M x x
PBYI ██% $466M 17.4x 3.4x
PCRX ██% $1.03B 70.5x 1.5x
PCSA ██% $6M x x
PCYN ██% $2M x 1.0x
PDSB ██% $11M x x
PEPG ██% $207M x 1.7x
PFE ██% $162.19B 37.4x 1.9x
PGEN ██% $2.48B x 56.9x
PHAT ██% $766M x x
PHIO ██% $13M x 1.0x
PHVS ██% $2.43B x x
PKTX ██% $80K x 0.3x
PLRX ██% $68M x 0.5x
PLYX ██% $100M x 9.2x
PMHS ██% $9M x x
PMN ██% $117M x 2.4x
PMVP ██% $70M x 1.0x
PPBT ██% $3M x x
PPCB ██% $2M x 0.3x
PRAX ██% $9.78B x 7.3x
PRFX ██% $3M x 0.3x
PRGO ██% $2.03B x 0.8x
PRLD ██% $447M x 3.3x
PRPH ██% $310K x x
PRQR ██% $301M x x
PRTA ██% $484M x 1.7x
PTCT ██% $5.79B x x
PTGX ██% $9.56B 115.3x 11.4x
PTIX ██% $2M x 1.3x
PTN ██% $18M x 1.7x
PTPI ██% $170K x 0.2x
PULM ██% $5M x 2.1x
PVCT ██% $24M x x
PVLA ██% $2.20B x 10.1x
PYXS ██% $270M x 23.6x
QNRX ██% $12M x 3.2x
QNTM ██% $20M x x
QTTB ██% $482M 14.3x 4.6x
QUCY ██% $132M x 6.5x
QURE ██% $3.21B x 21.5x
RADX ██% $33M x x
RANI ██% $120M x 3.1x
RAPP ██% $2.52B x 6.0x
RARE ██% $2.49B x x
RCKT ██% $407M x 1.1x
RCUS ██% $3.91B x 8.4x
RDY ██% $10.12B x x
REGN ██% $83.76B 19.4x 2.6x
REVB ██% $4M x 0.4x
RFL ██% $132M x 1.8x
RGBP ██% $170K x x
RIGL ██% $856M 2.7x 2.0x
RKTO ██% $16M x 2.0x
RLMD ██% $485M x 2.4x
RLYB ██% $89M 2.0x 0.9x
RMHI ██% $25M x x
RMTI ██% $33M x 1.0x
RNAC ██% $279M x x
RNAZ ██% $2M x x
RNTX ██% $69M x 1.2x
RNXT ██% $87M x 9.7x
ROIV ██% $25.03B x 5.9x
RPRX ██% $35.71B 43.8x 5.2x
RTEZ ██% $1.93B x x
RVPH ██% $7M x 0.4x
RVRC ██% $87M x 15.7x
RYTM ██% $7.30B x 70.9x
RZLT ██% $452M x 3.9x
SBFM ██% $5M x 0.2x
SCNX ██% $16M x 0.3x
SCYX ██% $56M x 0.8x
SDGR ██% $1.46B x 4.4x
SEPN ██% $1.74B x 4.5x
SER ██% $61M x 3.3x
SGMT ██% $638M x 2.5x
SHPH ██% $2M x 0.6x
SIGA ██% $226M x 1.4x
SILO ██% $4M x 0.9x
SION ██% $279M x 1.1x
SKVI ██% $970K x x
SKYE ██% $7M x x
SLGL ██% $226M x 9.9x
SLN ██% $841M x 21.9x
SLS ██% $2.69B x 19.6x
SMMT ██% $10.80B x 17.2x
SMNR ██% $127M x x
SNDX ██% $1.79B x 118.6x
SNGX ██% $8M x 1.2x
SNSE ██% $31M x x
SNY ██% $106.29B x x
SPRB ██% $162M x 1.9x
SPRC ██% $4M x x
SPRO ██% $71M 9.6x 1.6x
SPRY ██% $597M x 47.7x
SRPT ██% $2.22B 7.2x 1.5x
STOK ██% $1.95B x 5.6x
STTK ██% $706M x 3.3x
SUPN ██% $2.57B x 2.5x
SVRA ██% $1.11B x 7.7x
SXTP ██% $4M x 1.5x
SYBX ██% $14M x 1.2x
SYRE ██% $7.54B x 6.9x
TAK ██% $58.68B x x
TBPH ██% $884M 16.4x 3.1x
TCRT ██% $4M x 6.8x
TELO ██% $83M x 16.4x
TENX ██% $81M x 0.7x
TEVA ██% $41.86B 59.3x 5.4x
TGTX ██% $8.16B 18.5x 13.5x
TLPH ██% $62M x 4.3x
TLX ██% $3.69B x x
TNGX ██% $3.75B x 3.7x
TNXP ██% $232M x 1.0x
TOVX ██% $11M x 0.9x
TPST ██% $17M x x
TRDA ██% $267M x 1.1x
TRVI ██% $2.54B x 7.9x
TTRX ██% $278M x 404.8x
TVRD ██% $24M x 2.9x
TVTX ██% $6.23B x 254.0x
TXMD ██% $25M x 0.9x
TYRA ██% $1.57B x 4.5x
UNCY ██% $142M x 2.7x
UPB ██% $377M x 1.4x
URGN ██% $2.25B x x
UTHR ██% $22.02B 16.8x 3.4x
VBIO ██% $3M x 0.7x
VCNX ██% $2M x x
VERA ██% $2.46B x 6.0x
VGLS ██% $240K x x
VICP ██% $47M x x
VKTX ██% $3.83B x 9.4x
VNDA ██% $323M x 1.5x
VRCA ██% $94M x 21.9x
VRDN ██% $2.60B x 3.9x
VREOD ██% $491M x 1.7x
VREOF ██% $491M x 1.7x
VRTX ██% $139.28B 31.6x 6.9x
VSTM ██% $675M x 13.5x
VTGN ██% $11M x 0.5x
VTRS ██% $19.34B 7.4x 1.4x
VYNE ██% $19M x 0.8x
WHWK ██% $263M x 1.4x
WVE ██% $947M x 2.1x
XBIO ██% $10M x 1.6x
XBIT ██% $69M x 0.5x
XCUR ██% $8M x 8.0x
XENE ██% $6.03B x 4.9x
XERS ██% $1.47B x x
XLO ██% $59M x 0.8x
XNCR ██% $2.06B x 4.1x
XOMA ██% $710M 21.0x 7.7x
XTLB ██% $6M x x
ZBIO ██% $2.11B x 8.5x
ZLAB ██% $2.86B x 4.7x
ZNTL ██% $348M x 2.4x
ZTS ██% $31.33B 12.0x 10.0x
ZVRA ██% $705M 11.5x 3.2x
ZVSA ██% $800K x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Aquestive Therapeutics, Inc. Stock Forecast

How accurate are Aquestive Therapeutics, Inc. stock predictions?

Our AI model shows a 19% Spearman correlation coefficient for AQST predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Aquestive Therapeutics, Inc. stock price forecasts?

Our analysis considers Aquestive Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Aquestive Therapeutics, Inc. a good investment in 2026?

Based on our AI analysis, Aquestive Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Aquestive Therapeutics, Inc. forecasts updated?

Aquestive Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Aquestive Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...